Semaglutide Sublingual Drops: What the Evidence Actually Shows

The chemistry problem: why semaglutide doesn't dissolve under the tongue

Semaglutide is a large peptide molecule. Peptides are broken down rapidly by enzymes in the mouth, gut lining and intestinal wall, which is precisely why injectable semaglutide (Wegovy, Ozempic) bypasses that route entirely. The scientific challenge of getting semaglutide into the bloodstream via the gut took Novo Nordisk years to solve, and the solution was co-formulation with sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) a compound that transiently raises local pH and increases semaglutide absorption across the stomach lining. That mechanism is specific to a solid tablet swallowed whole, sitting against the stomach wall. Sublingual absorption relies on passive diffusion across the oral mucosa, a fundamentally different barrier, one that has not been shown in any peer-reviewed study to deliver clinically meaningful semaglutide concentrations. The OASIS 4 trial, which underpinned the MHRA's June 2026 approval of oral semaglutide for weight loss, studied the tablet formulation exclusively. No equivalent trial data exists for drops.

This is not a minor regulatory technicality. It means there is no published evidence that semaglutide sublingual drops deliver the medicine into the body at all, let alone at a dose sufficient to produce meaningful weight loss.

What the MHRA has approved, and what it hasn't

The MHRA's approval trail for semaglutide is straightforward. Ozempic (injectable semaglutide) is licensed for type 2 diabetes. Wegovy (injectable semaglutide 2.4mg, and now up to 7.2mg) is licensed for weight management. Wegovy tablets (the 1.5mg to 25mg once-daily oral schedule) became the first oral GLP-1 medicine licensed in the UK for weight management when the MHRA approved them on 11 June 2026, making the UK the first country in Europe to authorise them. Rybelsus tablets (3mg, 7mg, 14mg) are a separate oral semaglutide product licensed only for type 2 diabetes; they are not a weight-loss medicine and their dose ladder is entirely distinct from the Wegovy tablet schedule. Sublingual semaglutide in any form appears nowhere on that list. Products advertised as semaglutide drops are therefore either unlicensed, compounded without regulatory sign-off, or simply mislabelled. The MHRA has warned publicly that unlicensed GLP-1 products (including compounded and counterfeit preparations) have caused hospitalisations. You can report any suspect product at the MHRA Yellow Card scheme.

Semaglutide sublingual drops for weight loss: what sellers claim versus what the evidence says

Sellers of sublingual semaglutide drops typically claim the product is absorbed directly into the bloodstream via the mouth's blood vessels, bypassing the gut. This is plausible in principle for some small molecules, but semaglutide is not a small molecule. The molecular weight and peptide structure that make semaglutide such a precise GLP-1 receptor agonist also make it poorly suited to transmucosal absorption. No peer-reviewed pharmacokinetic study has demonstrated reliable sublingual bioavailability for semaglutide. In the absence of that data, sellers are effectively asking buyers to trust a mechanism that has never been clinically tested. That is a significant ask for a product being taken to manage a chronic health condition. For context, even the licensed injectable semaglutide schedule begins at 0.25mg and is titrated carefully by a prescriber over months, a process designed around a fully characterised pharmacokinetic profile. There is no equivalent profile for drops. Patients who have tried them without result sometimes contact our team having spent months on an ineffective product; a question our prescribers hear is whether any of that time counts as a trial of semaglutide treatment. Clinically, it does not. For a straightforward overview of the evidence base behind licensed options, the NHS semaglutide medicines page sets out what is known clearly. If you are comparing costs of legitimate treatment options, our Wegovy pricing page covers what private prescriptions typically include.

The licensed route, and what a clinical assessment involves

If you are looking for a non-injectable semaglutide option in the UK, the Wegovy tablet is currently the only licensed answer. It is a Prescription-Only Medicine, which means a prescriber must assess your health history, current medicines and BMI before one can be issued. That assessment exists because semaglutide affects gastric emptying, interacts with the absorption timing of other oral medicines, and is contraindicated in pregnancy and for people with certain GI conditions. Those factors matter regardless of the formulation. Oral contraceptive users, for example, are advised to take the pill at a different time of day when also taking oral semaglutide, because gastric-emptying changes can affect absorption. A prescriber will talk through this. At nume, every consultation (whether you submit it on a Monday morning or the Friday before a bank holiday) is read by a GPhC-registered Independent Prescriber, not processed by software. If treatment is clinically suitable, dispatch happens the same day for orders placed before 12pm. To explore whether licensed semaglutide treatment is right for you, speaking to our prescribers is a good starting point.